Insmed receives FDA approval for BRINSUPRI (brensocatib), first treatment for NCFB

INSMED Inc

FDA approved BRINSUPRI 10 mg and 25 mg for non-CF bronchiectasis in adults and children ≥12 years.
Phase 3 ASPEN: 21.1% (10 mg) and 19.4% (25 mg) reduction in annual exacerbation rate vs placebo.
Approximately 500,000 U.S. patients diagnosed with NCFB; first approved therapy for this condition.
BRINSUPRI available by prescription via specialty pharmacy; commercial launches in EU/UK/Japan expected 2026.
Insmed to host investor call today at 12:00 PM ET to discuss the approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.